Skip to content

National Vision

US · EYE #3082 by market cap Listed 2017
16.72 -0.29 -1.70%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Recent news

  • Barclays Maintains National Vision(EYE.US) With Buy Rating, Cuts Target Price to $24
    Market Newswire · 2026/11/13
  • Rating change
    Guggenheim Maintains National Vision(EYE.US) With Buy Rating, Cuts Target Price to $27
    Market Newswire · 2026/9/11
  • Rating change
    Aier Eye Hospital (300015): Earnings in the first half of 2026 are expected to be volatile, with the refractive surgery business posting rapid growth.
    开源证券 · 2026/8/28
  • Rating change
    Commentary on Huaxia Eye Hospital's (301267) Q3 2026 Financial Report: Profit growth rebounded significantly in the third quarter.
    Guolian Minsheng Securities · 2026/11/11
  • A Quick Look at Today's Ratings for National Vision(EYE.US), With a Forecast Between $20 to $31
    Market Newswire · 2026/11/14
  • Rating change
    Cat Eye Entertainment (01896.HK): Film business under short-term pressure; summer box-office season showing signs of recovery; IP business expanding steadily.
    Western Securities · 2026/9/1
  • Aier Eye Hospital: The proportion of advanced surgical procedures in the refractive business continued to rise in the third quarter.
    Latest · 2026/11/12
  • Company notice
    Fronteo: FRONTEO has added image data analysis capabilities to its AI monitoring solution "KIBIT Eye," which anticipates fraud risks and aims to prevent them before they occur.
    JPX · 2026/10/20
  • Aier Eye Hospital (300015.SZ): In the third quarter of 2026, the proportion of advanced surgical procedures such as ICL V5, SMILE Pro, and Quan Guang Su continued to rise, driving a significant sequential increase in revenue.
    Gelonghui Finance · 2026/11/12
  • Rating change
    Aier Eye Hospital (300015): Back tax payments impact short-term profits; H-share listing preparations strengthen internationalization.
    Citic Securities · 2026/9/30
  • Rating change
    Shanghai Harbor (605598): Short-term profit margins under pressure; keep an eye on developments in the commercial space sector.
    Huatai Securities · 2026/9/3
  • Company notice
    Fuva Brain: Eye "247" Work Smart Cloud has won the "ITreview Grid Award 2026 Fall" in two categories.
    JPX · 2026/10/22
  • Rating change
    Barclays Maintains National Vision(EYE.US) With Buy Rating, Maintains Target Price $27
    Market Newswire · 2026/9/10
  • Company notice
    Xingqi Eye Medicine: Legal Opinion of King & Wood Mallesons Beijing Office Regarding Matters Relating to the Adjustment of the Grant Price and Grant Quantity under the 2021 Restricted Stock Incentive Plan of Shenyang Xingqi Eye Medicine Co., Ltd., the Fulfillment of Vesting Conditions for the Fifth Vesting Period, and the Cancellation of Certain Restricted Shares
    SZSI · 2026/10/12
  • Zhaok Ophthalmology-B (06622.HK) has received marketing approval from the National Medical Products Administration for Jingyouling® (Cyclosporine Eye Gel), an innovative drug independently developed by the company.
    Gelonghui Finance · 2026/11/13
  • Company notice
    Needs Well: Promoting the development of data‑driven talent with an eye toward the AI era.
    JPX · 2026/9/29
  • Rating change
    Stifel Maintains KITS EYE CARE LTD(KTYCF.US) With Buy Rating, Cuts Target Price to $14.88
    Market Newswire · 2026/11/7
  • Company notice
    Institution for a Global Society: "AI GROW," which boasts a track record of assessing non-cognitive skills across 125 million data points, supports the "connection between learning and society" with an eye toward children's success after graduation.
    JPX · 2026/10/2
  • Rating change
    Xingqi Eye Medicine (300573): Steady performance growth in the first three quarters; innovative ophthalmic drug pipeline continues to advance.
    Huaan Securities · 2026/11/4
  • Rating change
    Roth MKM Maintains KITS EYE CARE LTD(KTYCF.US) With Buy Rating, Raises Target Price to $16.3
    Market Newswire · 2026/11/6
  • Rating change
    TopCloudAg (301556): Project timelines are weighing on near-term revenue; keep an eye on opportunities arising from business model evolution.
    CICC · 2026/8/28
  • Rating change
    Cat Eye Entertainment (1896.HK): Weak overall box office conditions weigh on earnings; attention focused on the performance of its slate of upcoming titles.
    Sealand Securities · 2026/8/25
  • Rating change
    Aier Eye Hospital (300015): Revenue in 26H1 grew steadily, with outpatient visits and surgical procedures continuing to rise.
    Guosen Securities · 2026/8/28
  • Bid with an eye on the market leader.
    Latest · 2026/10/30
  • Rating change
    Joyoung Co., Ltd. (002242): Keep an eye on the pace of subsequent domestic demand improvement and earnings recovery.
    Huatai Securities · 2026/8/25

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

National Vision discussion 0 comments

Add a comment